



Corporate Presentation

2008

Nutra Pharma Corporation
791 Park of Commerce Blvd., Suite 300
Boca Raton, FL 33487 USA

Investor Relations: (877) 895-5647

Office: (954) 509-0911

Fax: (877) 895-5647

Web: <http://www.NutraPharma.com>



SAFE HARBOR

Statements made in the course of this presentation that state the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future are forward-looking statements. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings, including but not limited to the Company's report on Form 10-K for the year ended December 31, 2007; the Company's report on Form 10-Q for the quarter ended March 31, 2008. Copies of these filings may be obtained by contacting the Company or the SEC.

TABLE OF CONTENTS

- Section I:** Nutra Pharma Overview
- Section II:** Drug Discovery
- Section III:** Medical Devices
- Section IV:** Conclusion



NUTRA PHARMA OVERVIEW

Who We Are

Nutra Pharma is a biopharmaceutical company that focuses on drug discovery for Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV) treatments and medical diagnostic test kits for Tuberculosis (TB) and Nontuberculous Mycobacteria (NTM).

Markets We Serve

The markets represent opportunities in excess of approximately \$25 Billion today.

Mission Statement

Nutra Pharma is dedicated to the success of its patients, customers, investors and business partners through its development and acquisition of innovative pharmaceutical and life science solutions that will improve the lives of people throughout the world.

Securities Associates (SA) estimates that presently \$200MM in new drug sales at a 50% margin represents \$2.5B in public market value, or roughly 12.5x revenue.

AREAS OF FOCUS

Drug Discovery

Through its wholly-owned subsidiary, ReceptoPharm, Nutra Pharma focuses on drug development of therapeutic proteins for the treatment of several chronic, life-threatening viral, auto-immune and neuro-degenerative disorders, specifically including HIV, AIDS, Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Muscular Dystrophy (MD), and Myasthenia Gravis (MG).

The combined markets for the drugs under development is in excess of \$25 Billion with Multiple Sclerosis (MS) representing a \$15 Billion market.

Medical Devices

Through its wholly-owned subsidiary, Designer Diagnostics, Nutra Pharma focuses on the development, marketing, and sales of medical diagnostic test kits for the rapid isolation and identification of infectious diseases such as Tuberculosis (TB) and Nontuberculous Mycobacteria (NTM), including Mycobacterium Avium-Intracellulare (MAI).

The market for these kits is expected to exceed \$300MM annually.

Drug Discovery

DRUG DISCOVERY

Areas of Focus

Nutra Pharma is applying bioscience to snake venom neurotoxins like cobratoxin for biopharmaceutical drug discovery and neurological therapeutics for HIV, AIDS, Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Muscular Dystrophy (MD), and Myasthenia Gravis (MG).

ReceptoPharm, Inc.

ReceptoPharm is the drug discovery arm for Nutra Pharma.

Leading Drug Candidates

RPI-MN: Modified Cobra Venom for Viral Diseases

RPI-78M: Modified Alpha Cobratoxin for Autoimmune and Neurological Diseases

Current drugs can only suppress and alleviate the symptoms, Nutra Pharma's drugs are said to be the first to promise the *reversal* of symptoms for some diseases.

DRUG DISCOVERY

Drug Applications

RPI-MN: Modified Cobra Venom for Viral Diseases

- HIV/AIDS (\$10B Market)
- Herpes
- Rabies

RPI-78M: Modified Alpha Cobratoxin for Autoimmune and Neurological Diseases

- Multiple Sclerosis (MS)
- Myasthenia Gravis
- Rheumatoid Arthritis (RA)
- Type-I Diabetes
- Hashimoto's Thyroiditis
- Scleroderma
- Psoriasis
- Adrenomyeloneuropathy (AMN)

Intellectual Property

Nutra Pharma holds potentially disruptive intellectual property related to the treatment of MS, AMN and HIV. Not only have the therapies shown indications of reversal of symptoms, but also promise to be ½ the cost of comparable therapies.

DRUG DISCOVERY

Benefits of Nutra Pharma's Multiple Sclerosis (MS) Treatment:

RPI-78M

- Disease Progression Stops
- Patient Conditions Improve
- No Significant Adverse Side Effects
- Long Shelf Life
- Resistant to Heat
- Patient Does Not Develop Resistance
- Improves Quality of Life

Competitive Drugs

- Disease Progression Only Slows
- No Claims Against Patient Improvement
- Adverse Side Effects Present – Some Severe
- Limited Shelf Life
- Requires Refrigeration
- Patient Develops Immune Resistance
- No Evidence for Quality of Life improvement

DRUG DISCOVERY

Benefits of Nutra Pharma's HIV/AIDS Treatment:

RPI-MN

- Mutations are Not Created
- Relatively Inexpensive
- No Significant Adverse Side Effects
- Long Shelf Life
- Patient Does Not Develop Resistance
- Easy to Manufacture

Fuzeon by Roche/Trimeris

- Mutations Are Created
- Very Expensive – Twice Current Therapies
- Adverse Side Effects Present – Some Severe
- Limited Shelf Life
- Patient Develops Immune Resistance
- Difficult Manufacturing Leads to Limited Use

Medical Devices



MEDICAL DEVICES

Areas of Focus

Nutra Pharma specializes in the development, marketing, and sales of medical diagnostic test kits for the rapid identification of organisms such as *M. avium*, Pseudomonads, MOTT or Atypical Mycobacteria, *Nocardia*, Nontuberculous Mycobacteria, *M. tuberculosis*, and Tuberculosis Complex.

Designer Diagnostics, Inc.

Designer Diagnostics is the medical devices sales and marketing arm of Nutra Pharma.

Intellectual Property

Nutra Pharma currently owns 11 patents and owns the rights to 18 additional patents for the test kit technology.

The market for these kits is expected to exceed \$300MM annually.

MEDICAL DEVICES

Benefits of Nutra Pharma's Medical Diagnostic Test Kits:

- Ability to provide much earlier diagnosis (less than 1 week)
- Long shelf life
- Can be stored in extremely hostile environments
- Cost effective compared to all other traditional methods
- Does not require new large capital expenditures
- Can be easily integrated into any lab environment from the most advanced to a simple mobile lab
- Results can be quickly translated into PCR testing and other antibiotic sensitivity testing techniques

Conclusion



CONCLUSION

Nutra Pharma is a biopharmaceutical company that focuses on drug discovery for Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN) and HIV treatments and medical diagnostic test kits for Tuberculosis (TB) and Nontuberculous Mycobacteria (NTM).

The markets of Nutra Pharma's subsidiaries, ReceptoPharm and Designer Diagnostics, represent opportunities in excess of approximately \$25 Billion today.

Securities Associates (SA) estimates that presently \$200MM in new drug sales at a 50% margin represents \$2.5B in public market value, or roughly 12.5x revenue.

Nutra Pharma holds intellectual property related to the treatment of MS, AMN and HIV. They also own 18 patents and own the rights to 11 additional patents for the test kit technology.

A number of competitive drugs in the MS market are being investigated by the FDA due to safety concerns and lack of efficacy. This provides new entrants to the market, such as Nutra Pharma, the opportunity to quickly increase market share.



Bringing Healthcare Solutions to the World

Visit us Online at www.NutraPharma.com